Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 3
1967 2
1968 4
1969 1
1970 4
1971 8
1972 10
1973 12
1974 3
1975 7
1976 7
1977 5
1978 6
1979 3
1980 2
1981 2
1982 4
1983 5
1984 7
1985 12
1986 14
1987 7
1988 7
1989 3
1990 4
1991 1
1992 5
1993 4
1994 3
1995 2
1996 5
1997 7
1998 2
1999 3
2000 2
2001 2
2002 2
2003 1
2004 3
2005 6
2006 4
2007 2
2008 6
2009 2
2010 7
2011 2
2012 2
2013 6
2014 5
2015 2
2016 1
2017 4
2019 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

233 results
Results by year
Filters applied: . Clear all
Page 1
Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma.
Rossi F, et al. Oncogene 2019. PMID 30670781 Free PMC article.
To deepen our knowledge about circ-ZNF609 role in cell cycle regulation, we studied its expression and function in rhabdomyosarcoma (RMS), a pediatric skeletal muscle malignancy. ...
To deepen our knowledge about circ-ZNF609 role in cell cycle regulation, we studied its expression and function in rhabdomyosarcoma ( …
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy
Highfill SL, et al. Sci Transl Med 2014. PMID 24848257 Free PMC article.
We sought to target these pathways in rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood. Murine RMS showed high surface expression of PD-L1, and anti-PD1 prevented tumor growth if initiated early after tumor inoculation; however, delayed anti-PD1 had limited benefit. ...
We sought to target these pathways in rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood. Murine RMS showed hig …
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.
De Giovanni C, et al. BMC Cancer 2019. PMID 30732578 Free PMC article.
We therefore studied the possibility to hamper rhabdomyosarcoma growth with passive and active immune approaches targeting IGF2. ...CONCLUSIONS: Immune targeting of autocrine IGF2 inhibited rhabdomyosarcoma genesis and metastatic growth....
We therefore studied the possibility to hamper rhabdomyosarcoma growth with passive and active immune approaches targeting IGF2. ...C …
Various checkpoint molecules, and tumor-infiltrating lymphocytes in common pediatric solid tumors: Possibilities for novel immunotherapy
Mochizuki K, et al. Pediatr Hematol Oncol 2019. PMID 30870043
Whereas the expression of GAL9 and MHC-II was limited, 73% of rhabdomyosarcomas and 100% of osteosarcomas expressed moderate to high levels of Herpes virus entry mediator on the tumor. ...Interestingly, 45% of rhabdomyosarcomas, and 45% of osteosarcomas expressed moderate to high levels of both Herpes virus entry mediator on the tumor cells and B- and T-lymphocyte attenuator on the TILs. ...
Whereas the expression of GAL9 and MHC-II was limited, 73% of rhabdomyosarcomas and 100% of osteosarcomas expressed moderate to high …
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.
Chen CY, et al. Sci Rep 2017. PMID 28539588 Free PMC article.
In syngeneic murine rhabdomyosarcoma models, we found that M3-9-M (MHC I high) but not 76-9 (MHC I low) tumors respond to oncolytic herpes simplex virus-1 (oHSV-1) and PD-1 blockade combination therapy. ...
In syngeneic murine rhabdomyosarcoma models, we found that M3-9-M (MHC I high) but not 76-9 (MHC I low) tumors respond to oncolytic h …
Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
Merchant MS, et al. Clin Cancer Res 2016 - Clinical Trial. PMID 26823601 Free article.
Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rhabdomyosarcoma vs. other sarcomas) and response to standard therapy (74% no residual disease vs. 0% residual disease). Five-year intent-to-treat OS of patients with newly diagnosed metastatic Ewing/rhabdomyosarcoma was 77%, higher than previously reported in this population and higher than observed in a similar group treated with an earlier adjuvant immunotherapy regimen (25% 5-year OS). ...
Intent-to-treat analysis demonstrated 5-year OS of 51% with significant differences based upon histologic group (63% vs. 0% for Ewing/rha
Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.
Dobson CC, et al. Oncotarget 2017. PMID 27966453 Free PMC article.
Rhabdomyosarcoma (RMS), a neoplasm characterized by undifferentiated myoblasts, is the most common soft tissue tumour in children. ...
Rhabdomyosarcoma (RMS), a neoplasm characterized by undifferentiated myoblasts, is the most common soft tissue tumour in children. ..
Targeting the fetal acetylcholine receptor in rhabdomyosarcoma.
Simon-Keller K, et al. Expert Opin Ther Targets 2013 - Review. PMID 23231343
INTRODUCTION: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Recent efforts to enhance overall survival of patients with clinically advanced RMS have failed and there is a demand for conceptually novel treatments. ...
INTRODUCTION: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Recent efforts to enhance o …
A Novel α9 Integrin Ligand, XCL1/Lymphotactin, Is Involved in the Development of Murine Models of Autoimmune Diseases
Matsumoto N, et al. J Immunol 2017. PMID 28550205 Free article.
Using α9 integrin-overexpressing NIH3T3 cells and endogenously α9 integrin-expressing human rhabdomyosarcoma cells, the interaction between XCL1 and α9 integrin was confirmed by pull-down assays. ...
Using α9 integrin-overexpressing NIH3T3 cells and endogenously α9 integrin-expressing human rhabdomyosarcoma cells, the interaction b …
233 results
Jump to page
Feedback